GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Stock Based Compensation

China Regenerative Medicine International (HKSE:08158) Stock Based Compensation : HK$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Stock Based Compensation?

China Regenerative Medicine International's Stock Based Compensation for the three months ended in Dec. 2024 was HK$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00 Mil.


China Regenerative Medicine International Stock Based Compensation Historical Data

The historical data trend for China Regenerative Medicine International's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International Stock Based Compensation Chart

China Regenerative Medicine International Annual Data
Trend Apr15 Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.23 2.16 - - -

China Regenerative Medicine International Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

China Regenerative Medicine International Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.


China Regenerative Medicine International Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


China Regenerative Medicine International Business Description

Traded in Other Exchanges
N/A
Address
132 Nathan Road, Suite 2310-18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.
Executives
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Wang Chuang 2101 Beneficial owner
Arab Osman Mohammed 2501 Other
Wong Kwok Keung 2501 Other
Lei Changjuan 2101 Beneficial owner
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Kong Yudong 2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Li Ren 2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited) 2201 Interest of corporation controlled by you
All Favour Holdings Limited 2101 Beneficial owner
Deng Shufen 2202 Interest of your spouse
Dai Yumin 2201 Interest of corporation controlled by you
Wang Xiaogang 2101 Beneficial owner
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines